Noriya Uedo

Noriya Uedo

Auto-generated profile, based on publicly available information

Noriya Uedo

Department of Gastrointestinal Oncology Osaka International Cancer Institute Osaka Japan

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 July 2019 in Gut
Verified
Journal Article
Open access
PDF file
MBMatthew R Banks
Matthew R Banks
DGDavid Graham
David Graham
MJMarnix Jansen
Marnix Jansen
TGTakuji Gotoda
Takuji Gotoda
SCSergio Coda
Sergio Coda
MDMario Dinis-Ribeiro
Mario Dinis-Ribeiro
Gastric adenocarcinoma carries a poor prognosis, in part due to the late stage of diagnosis. Risk factors include Helicobacter pylori infection, family history of gastric cancer—in particular, hereditary diffuse gastric cancer and pernicious anaemia. The stages in the progression to cancer include chronic gastritis, gastric atrophy (GA), gastric intestinal metaplasia (GIM) and dysplasia. The key to early detection of cancer and improved survival is to non-invasively identify those at risk before endoscopy. However, although biomarkers may help in the detection of patients with chronic atrophic gastritis, there is insufficient evidence to support their use for population screening. High-quality endoscopy with full mucosal visualisation is an important part of improving early detection. Image-enhanced endoscopy combined with biopsy sampling for histopathology is the best approach to detect and accurately risk-stratify GA and GIM. Biopsies following the Sydney protocol from the antrum, incisura, lesser and greater curvature allow both diagnostic confirmation and risk stratification for progression to cancer. Ideally biopsies should be directed to areas of GA or GIM visualised by high-quality endoscopy. There is insufficient evidence to support screening in a low-risk population (undergoing routine diagnostic oesophagogastroduodenoscopy) such as the UK, but endoscopic surveillance every 3 years should be offered to patients with extensive GA or GIM. Endoscopic mucosal resection or endoscopic submucosal dissection of visible gastric dysplasia and early cancer has been shown to be efficacious with a high success rate and low rate of recurrence, providing that specific quality criteria are met.

26 October 2020 in Digestive Endoscopy
Verified
Journal Article
Open access
PDF file
HOHiroyuki Ono
Hiroyuki Ono
KYKenshi Yao
Kenshi Yao
MFMitsuhiro Fujishiro
Mitsuhiro Fujishiro
IOIchiro Oda
Ichiro Oda
NUNoriya Uedo
Noriya Uedo
KFKazuma Fujimoto
Kazuma Fujimoto
In response to the rapid and wide acceptance and use of endoscopic treatments for early gastric cancer, the Japan Gastroenterological Endoscopy Society, in collaboration with the Japanese Gastric Cancer Association, produced “Guidelines for Endoscopic Submucosal Dissection and Endoscopic Mucosal Resection for Early Gastric Cancer” in 2014, as a set of basic guidelines in accordance with the principles of evidence‐based medicine. At the time, a number of statements had to be established by consensus (the lowest evidence level), as evidence levels remained low for many specific areas in this field. However, in recent years, the number of well‐designed clinical studies has been increasing. Based on new findings, we have issued the revised second edition of the above guidelines that cover the present state of knowledge. These guidelines are divided into the following seven categories: indications, preoperative diagnosis, techniques, evaluation of curability, complications, long‐term postoperative surveillance, and histology.

1 December 2011 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
YEYasumasa Ezoe
Yasumasa Ezoe
MMManabu Muto
Manabu Muto
NUNoriya Uedo
Noriya Uedo
HDHisashi Doyama
Hisashi Doyama
KYKenshi Yao
Kenshi Yao
YSYutaka Saito
Yutaka Saito

28 August 2006 in Endoscopy
Verified
Journal Article
Closed access
PDF file
NUN. Uedo
N. Uedo
RIR. Ishihara
R. Ishihara
HIH. Iishi
H. Iishi
SYS. Yamamoto
S. Yamamoto
TYT. Yamada
T. Yamada
MTM. Tatsuta
M. Tatsuta
Background and study aims: With endoscopy, there is a high rate of interobserver variability in the identification of gastric intestinal metaplasia, and the endoscopic findings correlate poorly with the histological findings. Previous studies by our group investigating the use of a narrow-band imaging system with magnifying endoscopy (NBI-ME) in the gastric mucosa suggested that the appearance of a light blue crest (LBC) on the epithelial surface may be a distinctive endoscopic finding associated with the presence of intestinal metaplasia. The aim of the present study was to clarify the value of NBI-ME for diagnosing gastric intestinal metaplasia. Patients and methods: The LBC was defined as a fine, blue-white line on the crests of the epithelial surface/gyri. To investigate the histology underlying the appearance of LBC, 44 biopsy specimens were obtained from regions containing LBC and 44 from non-LBC mucosa in 34 patients with atrophic gastritis. Three endoscopists then carried out NBI-ME in 107 consecutive patients to validate the diagnostic accuracy of the novel endoscopic technique. The degree of correlation between the LBC grading and the histological parameters of intestinal metaplasia was then assessed. Results: The LBC grading correlated with cells that were positive for CD10 (P = 0.0001) and Alcian blue (P = 0.036). The appearance of LBC correlated with histological evidence of intestinal metaplasia with a sensitivity of 89 % (95 % CI, 83 - 96 %), a specificity of 93 % (95 % CI, 88 - 97 %), a positive predictive value of 91 % (95 % CI, 85 - 96 %), a negative predictive value of 92 % (95 % CI, 87 - 97 %), and an accuracy of 91 % (95 % CI, 88 - 95 %). Conclusions: In narrow-band imaging with magnifying endoscopy, observation of a light blue crest on the epithelial surface in the gastric mucosa is a highly accurate sign of the presence of histological intestinal metaplasia.

1 December 2008 in Gastrointestinal Endoscopy
Verified
Journal Article
Closed access
RIRyu Ishihara
Ryu Ishihara
HIHiroyasu Iishi
Hiroyasu Iishi
NUNoriya Uedo
Noriya Uedo
YTYoji Takeuchi
Yoji Takeuchi
SYSachiko Yamamoto
Sachiko Yamamoto
MTMasaharu Tatsuta
Masaharu Tatsuta

1 April 2013 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
TYTakeshi Yamashina
Takeshi Yamashina
RIRyu Ishihara
Ryu Ishihara
KNKengo Nagai
Kengo Nagai
NMNoriko Matsuura
Noriko Matsuura
FMFumi Matsui
Fumi Matsui
HIHiroyasu Iishi
Hiroyasu Iishi
Long-term outcomes after endoscopic resection (ER) provide important information for the treatment of esophageal carcinoma. This study aimed to investigate the rates of survival and metastasis after ER of esophageal carcinoma. From 1995 to 2010, 570 patients with esophageal carcinoma were treated by ER. Of these, the 402 patients with squamous cell carcinoma (280 epithelial (EP) or lamina propria (LPM) cancer, 70 muscularis mucosa (MM) cancer, and 52 submucosal (SM) cancer) were included in our analysis. Seventeen patients had cancer invading into the submucosa up to 0.2 mm (SM1) and 35 patients had cancer invading into the submucosa more than 0.2 mm (SM2). The mean (range) follow-up time was 50 (4–187) months. The 5-year overall survival rates of patients with EP/LPM, MM, and SM cancer were 90.5, 71.1, and 70.8%, respectively (P=0.007). Multivariate analysis identified depth of invasion and age as independent predictors of survival, with hazard ratios of 3.6 for MM cancer and 3.2 for SM cancer compared with EP/LPM cancer, and 1.07 per year of age. The cumulative 5-year metastasis rates in patients with EP/LPM, MM, SM1, and SM2 cancer were 0.4, 8.7, 7.7, and 36.2%, respectively (P<0.001). Multivariate analysis identified depth of invasion as an independent risk factor for metastasis, with hazard ratios of 13.1 for MM, 40.2 for SM1, and 196.3 for SM2 cancer compared with EP/LPM cancer. The cumulative 5-year metastasis rates in patients with mucosal cancer with and without lymphovascular involvement were 46.7 and 0.7%, respectively (P<0.0001). The long-term risk of metastasis after ER was mainly associated with the depth of invasion. This risk should be taken into account when considering the indications for ER.